Company intelligence / Profile preview

Stemedica Cell Technologies

San Diego, California, United States

Ownership: Private
Employees: ~45
Development stage: Other

Overview

Stemedica has conducted multiple Phase 1 and Phase 2 trials. Notable results include a Phase 2a clinical trial for Alzheimer's disease using itMSC which met its primary safety endpoint and showed preliminary signals of cognitive stabilization. Their stroke trials have also demonstrated safety and improved motor function in some cohorts.

Therapeutic areas: CardiovascularNeurologyDermatology
Modalities: Stem cell therapyCell therapy
Industry: Biotech

Drug pipeline

1 asset

ischemia-tolerant mesenchymal stem cells

Partnerships

Alamo Bio-HealthGlobal Stem Cells Group

Beyond the preview

Go deeper on Stemedica Cell Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stemedica Cell Technologies.

Explore the full profile